OYSTER POINT PHARMA INC (OYST) Fundamental Analysis & Valuation

NASDAQ:OYST • US69242L1061

Current stock price

11.17 USD
+0.02 (+0.18%)
At close:
11.17 USD
0 (0%)
After Hours:

This OYST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. OYST Profitability Analysis

1.1 Basic Checks

  • OYST had negative earnings in the past year.
  • In the past year OYST has reported a negative cash flow from operations.
OYST Yearly Net Income VS EBIT VS OCF VS FCFOYST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 -20M -40M -60M -80M -100M

1.2 Ratios

  • OYST has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OYST Yearly ROA, ROE, ROICOYST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 -100 -200 -300

1.3 Margins

  • OYST does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OYST Yearly Profit, Operating, Gross MarginsOYST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. OYST Health Analysis

2.1 Basic Checks

  • OYST does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, OYST has more shares outstanding
  • The debt/assets ratio for OYST is higher compared to a year ago.
OYST Yearly Shares OutstandingOYST Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 5M 10M 15M 20M 25M
OYST Yearly Total Debt VS Total AssetsOYST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -7.49, we must say that OYST is in the distress zone and has some risk of bankruptcy.
  • OYST has a worse Altman-Z score (-7.49) than 76.71% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.49
ROIC/WACCN/A
WACC9.28%
OYST Yearly LT Debt VS Equity VS FCFOYST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 3.35 indicates that OYST has no problem at all paying its short term obligations.
  • The Current ratio of OYST (3.35) is worse than 69.57% of its industry peers.
  • OYST has a Quick Ratio of 3.11. This indicates that OYST is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.11, OYST is not doing good in the industry: 70.96% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.35
Quick Ratio 3.11
OYST Yearly Current Assets VS Current LiabilitesOYST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. OYST Growth Analysis

3.1 Past

  • OYST shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -113.14%.
  • OYST shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.15%.
EPS 1Y (TTM)-113.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-101.47%
Revenue 1Y (TTM)9.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-68.84%

3.2 Future

  • OYST is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.70% yearly.
  • Based on estimates for the next years, OYST will show a very strong growth in Revenue. The Revenue will grow by 105.78% on average per year.
EPS Next Y-66.47%
EPS Next 2Y4.31%
EPS Next 3Y14.43%
EPS Next 5Y-0.7%
Revenue Next Year55.43%
Revenue Next 2Y130.27%
Revenue Next 3Y117.27%
Revenue Next 5Y105.78%

3.3 Evolution

OYST Yearly Revenue VS EstimatesOYST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 200M 400M 600M
OYST Yearly EPS VS EstimatesOYST Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. OYST Valuation Analysis

4.1 Price/Earnings Ratio

  • OYST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OYST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OYST Price Earnings VS Forward Price EarningsOYST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OYST Per share dataOYST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as OYST's earnings are expected to grow with 14.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.31%
EPS Next 3Y14.43%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. OYST Dividend Analysis

5.1 Amount

  • No dividends for OYST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

OYST Fundamentals: All Metrics, Ratios and Statistics

OYSTER POINT PHARMA INC

NASDAQ:OYST (12/30/2022, 8:00:02 PM)

After market: 11.17 0 (0%)

11.17

+0.02 (+0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)02-22
Inst Owners0%
Inst Owner Change0%
Ins Owners31.31%
Ins Owner Change0%
Market Cap299.85M
Revenue(TTM)19.58M
Net Income(TTM)-176.65M
Analysts78
Price Target28.05 (151.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.77%
Min EPS beat(2)-10.44%
Max EPS beat(2)11.98%
EPS beat(4)1
Avg EPS beat(4)-3.32%
Min EPS beat(4)-13.56%
Max EPS beat(4)11.98%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-13.2%
Min Revenue beat(2)-20.89%
Max Revenue beat(2)-5.52%
Revenue beat(4)2
Avg Revenue beat(4)518.44%
Min Revenue beat(4)-20.89%
Max Revenue beat(4)2055.56%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.77%
PT rev (3m)N/A
EPS NQ rev (1m)0.9%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.16%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-8.11%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.96%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.31
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.65
EYN/A
EPS(NY)-3.53
Fwd EYN/A
FCF(TTM)-6.2
FCFYN/A
OCF(TTM)-6.18
OCFYN/A
SpS0.73
BVpS-0.83
TBVpS-0.83
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 140.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.35
Quick Ratio 3.11
Altman-Z -7.49
F-Score2
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)976.06%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-113.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-101.47%
EPS Next Y-66.47%
EPS Next 2Y4.31%
EPS Next 3Y14.43%
EPS Next 5Y-0.7%
Revenue 1Y (TTM)9.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-68.84%
Revenue Next Year55.43%
Revenue Next 2Y130.27%
Revenue Next 3Y117.27%
Revenue Next 5Y105.78%
EBIT growth 1Y-98.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year59.36%
EBIT Next 3Y-9.7%
EBIT Next 5Y-2.78%
FCF growth 1Y-206.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-208%
OCF growth 3YN/A
OCF growth 5YN/A

OYSTER POINT PHARMA INC / OYST Fundamental Analysis FAQ

What is the ChartMill fundamental rating of OYSTER POINT PHARMA INC (OYST) stock?

ChartMill assigns a fundamental rating of 1 / 10 to OYST.


What is the valuation status for OYST stock?

ChartMill assigns a valuation rating of 0 / 10 to OYSTER POINT PHARMA INC (OYST). This can be considered as Overvalued.


Can you provide the profitability details for OYSTER POINT PHARMA INC?

OYSTER POINT PHARMA INC (OYST) has a profitability rating of 0 / 10.